Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Update Il y a 4 ans
Reference: NCT00813072

Woman and Man

Extract

The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma


Inclusion criteria

  • Stomach Neoplasms ,Esophageal Neoplasms


Links